What question did this study set out to answer?

This research aims to assess the effectiveness and safety of sustained-release verapamil in patients with essential hypertension in typical clinical settings.

June 1, 1995American Journal of Therapeutics

Large-Scale Postmarketing Surveillance of Hypertensive Patients Treated With Verapamil

View Full Paper

Ask AI

Bookmark

Why the study?

Does once-daily sustained-release verapamil safely reduce blood pressure in patients with essential hypertension?

Population

25,089 patients with essential hypertension

Design

Cohort, open-label

Follow-up

4 weeks

Authors

MCMargaret M. CobbJanssen (United Kingdom)DJDeborah L. JohnsonBaylor College of Medicine JGJose GalloJohnson University

Discussion

Member takes

Implication

Large cohort links verapamil to graded DBP reductions; leaves open randomized confirmation before practice change.

Key Points

This research aims to assess the effectiveness and safety of sustained-release verapamil in patients with essential hypertension in typical clinical settings.
Prospective, open-label, postmarketing surveillance study
25,089 patients treated with once-daily verapamil for 4 weeks
Evaluated by 8106 physicians at baseline and two follow-ups (weeks 2 and 4)
85% of participants (n=21,446) completed the study
Reductions in diastolic blood pressure by 12, 19, and 29 mm Hg in mild, moderate, and severe cases respectively
6.1% experienced adverse events leading to study discontinuation, with only 4.5% related to the drug

Structured PICO

Does once-daily sustained-release verapamil safely reduce blood pressure in patients with essential hypertension?

Population

25,089 patients with essential hypertension (defined as average sitting DBP ≥90 mm Hg at baseline, or previously diagnosed with DBP <90 mm Hg but experiencing untoward effects requiring discontinuation of current antihypertensive therapy)

Intervention

Sustained-release verapamil once-daily for 4 weeks

Outcome

Effectiveness (blood pressure reduction) and safety (adverse events) at 4 weekssurrogate

In a large postmarketing surveillance study, once-daily sustained-release verapamil effectively reduced blood pressure and was well tolerated in a broad range of patients with essential hypertension.

Cite This Study

Cobb et al. (1995) studied this question.

synapsesocial.com/papers/6a7225e66c240de38cdc512a https://doi.org/10.1097/00045391-199506000-00003

View Full Paper

Ask AI

Bookmark

Large-Scale Postmarketing Surveillance of Hypertensive Patients Treated With Verapamil

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Large-Scale Postmarketing Surveillance of Hypertensive Patients Treated With Verapamil

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider